156 related articles for article (PubMed ID: 37887398)
1. Metabolic Analysis of DFO-Resistant Huh7 Cells and Identification of Targets for Combination Therapy.
Fujisawa K; Matsumoto T; Yamamoto N; Yamasaki T; Takami T
Metabolites; 2023 Oct; 13(10):. PubMed ID: 37887398
[TBL] [Abstract][Full Text] [Related]
2. An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells.
Fujisawa K; Takami T; Matsumoto T; Yamamoto N; Yamasaki T; Sakaida I
Cancer Metab; 2022 May; 10(1):8. PubMed ID: 35550011
[TBL] [Abstract][Full Text] [Related]
3. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth.
Lang J; Zhao X; Wang X; Zhao Y; Li Y; Zhao R; Cheng K; Li Y; Han X; Zheng X; Qin H; Geranpayehvaghei M; Shi J; Anderson GJ; Hao J; Ren H; Nie G
ACS Nano; 2019 Feb; 13(2):2176-2189. PubMed ID: 30676731
[TBL] [Abstract][Full Text] [Related]
4. Deferoxamine Counteracts Cisplatin Resistance in A549 Lung Adenocarcinoma Cells by Increasing Vulnerability to Glutamine Deprivation-Induced Cell Death.
Liu WJ; Pan PY; Sun Y; Wang JB; Zhou H; Xie X; Duan ZY; Dong HY; Chen WN; Zhang LD; Wang C
Front Oncol; 2021; 11():794735. PubMed ID: 35127502
[TBL] [Abstract][Full Text] [Related]
5. Iron chelator Deferoxamine protects human neuroblastoma cell line SH-SY5Y from 6-Hydroxydopamine-induced apoptosis and autophagy dysfunction.
Rakshit J; Priyam A; Gowrishetty KK; Mishra S; Bandyopadhyay J
J Trace Elem Med Biol; 2020 Jan; 57():126406. PubMed ID: 31570251
[TBL] [Abstract][Full Text] [Related]
6. The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.
Wang L; Li X; Mu Y; Lu C; Tang S; Lu K; Qiu X; Wei A; Cheng Y; Wei W
J Trace Elem Med Biol; 2019 Dec; 56():131-138. PubMed ID: 31466045
[TBL] [Abstract][Full Text] [Related]
7. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
8. Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells.
Moon JH; Jeong JK; Park SY
Oncol Rep; 2015 Mar; 33(3):1171-6. PubMed ID: 25524470
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
10. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
11. Deferoxamine stimulates LDLR expression and LDL uptake in HepG2 cells.
Guillemot J; Asselin MC; Susan-Resiga D; Essalmani R; Seidah NG
Mol Nutr Food Res; 2016 Mar; 60(3):600-8. PubMed ID: 26577249
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
13. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
[TBL] [Abstract][Full Text] [Related]
14. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Farr AC; Xiong MP
Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
[TBL] [Abstract][Full Text] [Related]
15. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity.
Umemura M; Kim JH; Aoyama H; Hoshino Y; Fukumura H; Nakakaji R; Sato I; Ohtake M; Akimoto T; Narikawa M; Tanaka R; Fujita T; Yokoyama U; Taguri M; Okumura S; Sato M; Eguchi H; Ishikawa Y
J Pharmacol Sci; 2017 Aug; 134(4):203-210. PubMed ID: 28779994
[TBL] [Abstract][Full Text] [Related]
16. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
17. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
18. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
Richardson D; Ponka P; Baker E
Cancer Res; 1994 Feb; 54(3):685-9. PubMed ID: 8306330
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice.
Hann HW; Stahlhut MW; Rubin R; Maddrey WC
Cancer; 1992 Oct; 70(8):2051-6. PubMed ID: 1327484
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation therapy.
Hershko CM; Link GM; Konijn AM; Cabantchik ZI
Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
